Anzeige
Erschienen in:
22.08.2016 | General Gynecology
Gonadotropin-releasing hormone agonist with add–back treatment is as effective and tolerable as dienogest in preventing pain recurrence after laparoscopic surgery for endometriosis
Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 6/2016
Einloggen, um Zugang zu erhaltenAbstract
Purpose
This study was performed to compare the efficacy and tolerability of GnRH agonist with add–back therapy versus dienogest treatment for preventing pelvic pain recurrence after laparoscopic surgery for endometriosis.
Methods
Sixty-four reproductive-aged women who underwent laparoscopic surgery for endometriosis received post-operative medical treatment with either GnRH agonist plus 17β-estradiol and norethisterone acetate (n = 28) or dienogest (n = 36) for 6 months. The pre- to post-treatment changes in pain were assessed using a visual analogue scale, and changes in quality-of-life and menopausal symptoms were measured by questionnaire.
Results
Visual analogue scale pain score decreased significantly for both treatments with no significant differences between groups. Neither physical, psychological, social, and environmental components of quality-of-life nor menopausal rating scale score were significantly different between the two groups. Bone mineral density at the lumbar spine declined significantly in both treatment groups (−2.5 % for GnRH agonist plus add–back and −2.3 % for dienogest), with no significant difference between the two groups.
Conclusion
GnRH agonist and add–back therapy using 17β-estradiol and norethisterone acetate are as effective and tolerable as dienogest for the prevention of pelvic pain recurrence after laparoscopic surgery for endometriosis.